Moderate kidney disease inhibits atherosclerosis regression

Atherosclerosis

Volumn 210, Issue 1, 2010, Pages 57-62

  Ponda, Manish P ^a,b   Barash, Irina ^b   Feig, Jonathan E ^b   Fisher, Edward A ^b   Skolnik, Edward Y ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Atherosclerosis regression; Chemokine receptor; Kidney disease; Serum response factor

Indexed keywords

APOLIPOPROTEIN E; CALCIUM; CHEMOKINE RECEPTOR CCR7; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; NITROGEN; PHOSPHORUS; SECONDARY LYMPHOID TISSUE CHEMOKINE; SERUM RESPONSE FACTOR; UREA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA GRAFT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DOWN REGULATION; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ANALYSIS; HYPERCHOLESTEROLEMIA; KIDNEY FUNCTION; MACROPHAGE; MALE; MORBIDITY; MORTALITY; MOUSE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; REMISSION; RISK FACTOR; SIGNAL TRANSDUCTION; UPREGULATION; UREA NITROGEN BLOOD LEVEL; UREMIA;

ANIMALS; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELL COUNT; DISEASE MODELS, ANIMAL; DOWN-REGULATION; KIDNEY FAILURE, CHRONIC; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, CCR7; SERUM RESPONSE FACTOR;

EID: 77952369013     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.10.029     Document Type: Article

References (25)

1. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
2. Beddhu S., Cheung A.K., Larive B., et al. Inflammation and inverse associations of body mass index and serum creatinine with mortality in hemodialysis patients. J Ren Nutr 2007, 17:372-380.
3. Reis S.E., Olson M.B., Fried L., et al. Mild renal insufficiency is associated with angiographic coronary artery disease in women. Circulation 2002, 105:2826-2829.
4. Chen R., Kumar S., Timmis A., et al. Comparison of the relation between renal impairment, angiographic coronary artery disease, and long-term mortality in women versus men. Am J Cardiol 2006, 97:630-632.
5. Bro S., Bentzon J.F., Falk E., et al. Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice. J Am Soc Nephrol 2003, 14:2466-2474.
6. Massy Z.A., Ivanovski O., Nguyen-Khoa T., et al. Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout mice. J Am Soc Nephrol 2005, 16:109-116.
7. Shepherd J., Kastelein J.J., Bittner V., et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008, 51:1448-1454.
8. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
9. Fellstrom B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360:1395-1407.
10. Williams K.J., Feig J.E., Fisher E.A. Cellular and molecular mechanisms for rapid regression of atherosclerosis: from bench top to potentially achievable clinical goal. Curr Opin Lipidol 2007, 18:443-450.
11. Williams K.J., Feig J.E., Fisher E.A. Rapid regression of atherosclerosis: insights from the clinical and experimental literature. Nat Clin Pract Cardiovasc Med 2008, 5:91-102.
12. Chereshnev I., Trogan E., Omerhodzic S., et al. Mouse model of heterotopic aortic arch transplantation. J Surg Res 2003, 111:171-176.
13. Llodra J., Angeli V., Liu J., et al. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci USA 2004, 101:11779-11784.
14. Trogan E., Fayad Z.A., Itskovich V.V., et al. Serial studies of mouse atherosclerosis by in vivo magnetic resonance imaging detect lesion regression after correction of dyslipidemia. Arterioscler Thromb Vasc Biol 2004, 24:1714-1719.
15. Trogan E., Feig J.E., Dogan S., et al. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci USA 2006, 103:3781-3786.
16. Susztak K., Bitzer M., Meyer T.W., Hostetter T.H. Animal models of renal disease. Kidney Int 2008, 73:526-528.
17. Kirchhoff F., Krebs C., Abdulhag U.N., et al. Rapid development of severe end-organ damage in C57BL/6 mice by combining DOCA salt and angiotensin II. Kidney Int 2008, 73:643-650.
18. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
19. Buzello M., Tornig J., Faulhaber J., et al. The apolipoprotein E knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 2003, 14:311-316.
20. Posern G., Treisman R. Actin together: serum response factor, its cofactors and the link to signal transduction. Trends Cell Biol 2006, 16:588-596.
21. Riol-Blanco L., Sanchez-Sanchez N., Torres A., et al. The chemokine receptor CCR7 activates in dendritic cells two signaling modules that independently regulate chemotaxis and migratory speed. J Immunol 2005, 174:4070-4080.
22. D'Intini V., Bordoni V., Bolgan I., et al. Monocyte apoptosis in uremia is normalized with continuous blood purification modalities. Blood Purif 2004, 22:9-12.
23. Zuo Y., Yancey P., Castro I., et al. Renal dysfunction potentiates foam cell formation by repressing ABCA1. Arterioscler Thromb Vasc Biol 2009, 29:1277-1282.
24. Wang Z., Nicholls S.J., Rodriguez E.R., et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007, 13:1176-1184.
25. Ponda M.P., Barash I. Lipid metabolism in dialysis patients - the story gets more complicated. Semin Dial 2008, 21:390-394.